PD-L1-H
|
HER2 Positive Breast Cancer
|
PD-L1-H
|
HER2 Positive Breast Cancer
|
trastuzumab Resistant: B - Late Trials
|
trastuzumab Resistant: B - Late Trials
|
PD-L1-H
|
NHL
|
PD-L1-H
|
NHL
|
L/P-VIPD Resistant: C3 – Early Trials
|
L / P-VIPD Resistant: C3 – Early Trials
|
PD-L1-H
|
Urothelial Cancer
|
PD-L1-H
|
Urothelial Cancer
|
atezolizumab Sensitive: C3 – Early Trials
|
atezolizumab Sensitive: C3 – Early Trials
|
PD-L1-H
|
NSCLC
|
PD-L1-H
|
NSCLC
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
PD-L1-H
|
Bladder Cancer
|
PD-L1-H
|
Bladder Cancer
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
PD-L1-H
|
NSCLC
|
PD-L1-H
|
NSCLC
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
PD-L1-H
|
Neuroendocrine Tumor
|
PD-L1-H
|
Neuroendocrine Tumor
|
everolimus Resistant: C3 – Early Trials
|
everolimus Resistant: C3 – Early Trials
|
PD-L1-H
|
CRC
|
PD-L1-H
|
CRC
|
durvalumab + CP-675206 Resistant: C3 – Early Trials
|
durvalumab + CP-675206 Resistant: C3 – Early Trials
|
PD-L1-H
|
Solid Tumor
|
PD-L1-H
|
Solid Tumor
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PD-L1-H
|
Urothelial Cancer
|
PD-L1-H
|
Urothelial Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PD-L1-H
|
Small Cell Lung Cancer
|
PD-L1-H
|
Small Cell Lung Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PD-L1-H
|
Melanoma
|
PD-L1-H
|
Melanoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PD-L1-H
|
Lung Cancer
|
PD-L1-H
|
Lung Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|